MarketCap
Facebook
X
Telegram
Tenax Therapeutics Net Debt | TENX
Net Debt can be roughly defined as financial liabilities that an entity classifies in the financing section together with the resources available to service those financial liabilities[1]
Net debt is the obligations that remain after deducting all assets and other liabilities from a company or individual. It represents the sum of debts that an organization or person must repay to their creditors or other parties.
Net debt can include various types of obligations such as loans, borrowings, lease liabilities, or credit card payments. It is important to note that net debt does not include current expenses or obligations such as payroll expenses or current bills.
Assessing net debt is an important financial indicator for evaluating the financial position of a company or individual. If net debt significantly exceeds assets, it may indicate financial difficulties and insolvency. In such cases, the company or individual may face difficulties in meeting their obligations and managing their finances.
Net debt can also be used to compare the financial stability of different companies. The lower the net debt relative to assets, the more stable and financially sound they are considered.
Overall, understanding net debt helps evaluate the financial soundness and ability of a company to meet their obligations. It is an important indicator that assists in making decisions about lending, investments, and financial management.
Annual Net Debt Tenax Therapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 1967 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | -2.06 M | -5.29 M | -6.25 M | -4.73 M | -12.4 M | -1.6 M | -10 M | -7.83 M | -58 M | 2.27 M | -456 K | 3.55 M | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 3.55 M | -58 M | -8.56 M |
References
- Pizzo, M., Moscariello, N., & Vinciguerra, R. (2015). Market Incentives and Regulators' Activity Shaping Financial Information: An Analysis of the Net Debt Disclosure in Italy. International Journal of Business and Management, 10(1), 1.
Net Debt of other stocks in the Biotechnology industry
| Issuer | Net Debt | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Catalyst Pharmaceuticals
CPRX
|
-706 M | - | - | $ 3.85 B |  USA |
 |
ARCA biopharma
ABIO
|
-45 M | - | 1052.0 % | $ 415 M | USA |
 |
Acasti Pharma
ACST
|
-27.4 M | - | 4.01 % | $ 150 M |  Canada |
 |
ADiTx Therapeutics
ADTX
|
-2.36 M | - | - | $ 374 | USA |
 |
Aeterna Zentaris
AEZS
|
-5.16 M | - | 5.93 % | $ 314 M | Canada |
 |
AgeX Therapeutics
AGE
|
71 K | - | -10.17 % | $ 12.2 K | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-30.2 M | - | - | $ 1.01 B | USA |
 |
AIkido Pharma
AIKI
|
-31.2 M | - | 1.93 % | $ 17.4 M | USA |
 |
Aileron Therapeutics
ALRN
|
-3.44 M | - | 10.36 % | $ 9.8 M | USA |
 |
AlloVir
ALVR
|
-96.6 M | - | 4.14 % | $ 49.1 M | USA |
 |
Apellis Pharmaceuticals
APLS
|
-311 M | - | - | $ 5.18 B | USA |
 |
Athira Pharma
ATHA
|
-68.5 M | - | - | $ 269 M | USA |
 |
Avenue Therapeutics
ATXI
|
-3.13 K | - | -52.27 % | $ 4.45 M | USA |
 |
AVROBIO
AVRO
|
-253 M | - | 1083.1 % | $ 745 M | USA |
 |
AstraZeneca PLC
AZN
|
-3.91 B | - | - | $ 96.9 B |  Britain |
 |
Brainstorm Cell Therapeutics
BCLI
|
533 K | - | -2.5 % | $ 5.88 M | USA |
 |
BeiGene, Ltd.
BGNE
|
-3.56 B | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Bio-Path Holdings
BPTH
|
-939 K | - | - | $ 100 K | USA |
 |
Cara Therapeutics
CARA
|
-20.5 M | - | -3.03 % | $ 260 M | USA |
 |
ChromaDex Corporation
CDXC
|
-62 M | - | -0.88 % | $ 598 M | USA |
 |
Caladrius Biosciences
CLBS
|
-22.3 M | - | -16.75 % | $ 25.8 M | USA |
 |
Cyclacel Pharmaceuticals
CYCC
|
-3.5 M | - | -5.98 % | $ 34.1 M | USA |
 |
Cyclacel Pharmaceuticals
CYCCP
|
-3.5 M | - | -4.36 % | $ 27 M | USA |
 |
Diffusion Pharmaceuticals
DFFN
|
-17.9 M | - | 11.68 % | $ 8.97 M | USA |
 |
Eloxx Pharmaceuticals
ELOX
|
611 K | - | -5.68 % | $ 8.28 M | USA |
 |
Enochian Biosciences
ENOB
|
-1.36 M | - | - | $ 40.5 M | USA |
 |
Esperion Therapeutics
ESPR
|
-165 M | - | - | $ 661 M | USA |
 |
Evofem Biosciences
EVFM
|
-396 K | - | 7.55 % | $ 38.1 M | USA |
 |
Eyenovia
EYEN
|
-5.72 M | - | 49.81 % | $ 13.2 M | USA |
 |
FibroGen
FGEN
|
27.1 M | - | - | $ 889 M | USA |
 |
Homology Medicines
FIXX
|
-42.7 M | - | 0.77 % | $ 53.4 M | USA |
 |
Amicus Therapeutics
FOLD
|
187 M | - | - | $ 4.47 B | USA |
 |
Frequency Therapeutics
FREQ
|
21.7 M | - | - | $ 528 M | USA |
|
Galecto
GLTO
|
-258 M | - | - | $ 762 M |  Danmark |
 |
GlycoMimetics
GLYC
|
-212 M | - | 9357.83 % | $ 1.01 B | USA |
 |
Graybug Vision
GRAY
|
-33.4 M | - | -11.23 % | $ 9.65 M | USA |
|
Galera Therapeutics
GRTX
|
-17 M | - | -32.59 % | $ 7.61 M | USA |
 |
Happiness Biotech Group Limited
HAPP
|
-10.1 M | - | 1.35 % | $ 17.8 M |  China |
 |
Hepion Pharmaceuticals
HEPA
|
-14.6 M | - | -18.79 % | $ 39.3 K | USA |
 |
Hoth Therapeutics
HOTH
|
-7.01 M | - | - | $ 18.8 M | USA |
 |
IMARA
IMRA
|
-74.9 M | - | 15.96 % | $ 663 M | USA |
 |
KalVista Pharmaceuticals
KALV
|
-55.5 M | - | - | $ 1.45 B | Britain |
 |
KemPharm
KMPH
|
-59 K | - | -0.34 % | $ 200 M | USA |
 |
Kezar Life Sciences
KZR
|
-33.1 M | - | - | $ 53.3 M | USA |
 |
Lixte Biotechnology Holdings
LIXT
|
-4.07 M | - | - | $ 63.4 M | USA |
 |
Magenta Therapeutics
MGTA
|
-49.7 M | - | -7.74 % | $ 41.6 M | USA |
 |
NovaBay Pharmaceuticals
NBY
|
-7.25 M | - | - | $ 11.3 M | USA |
 |
NeuroBo Pharmaceuticals
NRBO
|
-10.1 M | - | 0.43 % | $ 12 M | USA |
 |
OncoCyte Corporation
OCX
|
-3.24 M | - | 17.22 % | $ 355 K | USA |
 |
Onconova Therapeutics
ONTX
|
-19 M | - | -0.47 % | $ 21 M | USA |